James K Mangan
Overview
Explore the profile of James K Mangan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
437
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kim G, Burns J, Freyer C, Hamilton K, Frey N, Gill S, et al.
Am J Hematol
. 2020 Apr;
95(7):792-798.
PMID: 32242967
Invasive fungal infections (IFI) are a significant source of morbidity and mortality for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Given the heterogeneity of the population receiving...
12.
Frey N, Shaw P, Hexner E, Pequignot E, Gill S, Luger S, et al.
J Clin Oncol
. 2019 Dec;
38(5):415-422.
PMID: 31815579
Purpose: The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel (CTL019) has an 81% response rate in children with relapsed or chemotherapy refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). Cytokine release...
13.
Mistry R, Hexner E, Mangan J
Case Rep Hematol
. 2019 Oct;
2019:8437805.
PMID: 31612087
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive postthymic T-cell neoplasm with an associated survival time of 1 year when left untreated. Current standard of care for T-PLL is...
14.
Freyer C, Mangan J
J Oncol Pharm Pract
. 2018 Dec;
25(8):2035-2037.
PMID: 30537918
We describe a case of dose-related periorbital edema in a patient with FLT3-mutated acute myeloid leukemia taking sorafenib and voriconazole that resolved following sorafenib dose reduction. We hypothesize that the...
15.
Ganetsky A, Han J, Hughes M, Babushok D, Frey N, Gill S, et al.
Clin Infect Dis
. 2018 Sep;
68(12):2003-2009.
PMID: 30256954
Background: Clostridium difficile infection (CDI) is a leading cause of infectious complications in allogeneic hematopoietic cell transplant recipients (alloHCT). We sought to evaluate whether prophylactic oral vancomycin reduces the incidence...
16.
Ganetsky A, Frey N, Hexner E, Loren A, Gill S, Luger S, et al.
Bone Marrow Transplant
. 2018 May;
54(2):212-217.
PMID: 29795429
Steroid-refractory (SR) acute gastrointestinal (GI) graft-versus-host disease (GVHD) is associated with significant mortality in allogeneic hematopoietic cell transplantation recipients. We retrospectively evaluated the efficacy of tocilizumab for the treatment of...
17.
Kasner M, Mick R, Jeschke G, Carabasi M, Filicko-OHara J, Flomenberg N, et al.
Invest New Drugs
. 2018 Apr;
36(4):657-666.
PMID: 29607465
Background Mammalian Target of Rapamycin Complex 1 (mTORC1) inhibitors enhance chemotherapy response in acute myelogenous leukemia (AML) cells in vitro. However whether inhibiting mTORC1 enhances clinical response to AML chemotherapy...
18.
Hogan J, Loren A, Denker M, Mangan J
Leuk Lymphoma
. 2016 Dec;
58(8):2008-2010.
PMID: 27998198
No abstract available.
19.
Yam C, Crisalli L, Luger S, Loren A, Hexner E, Frey N, et al.
Am J Hematol
. 2016 May;
91(9):883-7.
PMID: 27197602
Reduced intensity allogeneic stem cell transplantation (RI alloSCT) is a potentially curative treatment approach for patients with myelodysplastic syndrome (MDS). It is currently unclear if older related donors are better...
20.
Mangan J, Chmieliauskaite M, Stoopler E
JAMA Oncol
. 2016 Apr;
2(5):679-680.
PMID: 27031778
No abstract available.